Salvage regimens for Hodgkin lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Hodgkin lymphoma (HL) relapse or refractoriness after primary therapy necessitates effective salvage strategies.
• Autologous stem cell transplantation is a standard of care for chemosensitive relapsed or refractory HL.

Purpose of the Study:

• To review current and novel salvage chemotherapy regimens for relapsed or refractory Hodgkin lymphoma.
• To discuss treatment options for patients progressing after initial salvage or autologous transplantation.

Main Methods:

• Literature review of phase II and III clinical trials on salvage chemotherapy for Hodgkin lymphoma.
• Summary of established and emerging treatment modalities, including gemcitabine-based regimens and investigational agents.

Main Results:

• Multiple salvage chemotherapy regimens demonstrate efficacy in relapsed/refractory HL.
• High-dose chemotherapy with autologous stem cell transplantation is a highly effective standard for chemosensitive disease.
• Options for refractory disease include further salvage, allogeneic transplantation, and novel agents.

Conclusions:

• Salvage therapy choice depends on response rate, toxicity, and stem cell collection impact.
• Ongoing research into novel therapies offers new avenues for patients with refractory Hodgkin lymphoma.